newborn screening (NBS)

新生儿筛查 ( NBS )
  • 文章类型: Journal Article
    背景:格雷夫斯病与不良妊娠有关,人工和交付,和新生儿结局。甲状腺功能水平,在新生儿筛查(NBS)期间评估,可以作为下丘脑-垂体-甲状腺轴适应的指标。我们利用来自国家甲状腺NBS计划的数据来调查患有过去或活动性Graves病的母亲所生的足月婴儿的母婴二联的特征。
    方法:将以色列NBS的甲状腺功能数据集与三级医疗中心的电子记录相关联,以生成2011年至2021年出生的母亲及其足月婴儿的统一数据库。MDClone大数据平台提取了母体,怀孕,病程,人工和交付,和母婴二叉的新生儿特征。
    结果:在103,899个登记的母婴二叉中,292名(0.3%)母亲患有过去或活动性格雷夫斯病。正向多元线性回归表明Graves病对NBS总甲状腺素(TT4)水平无显著影响(p=0.252)。患有活动性Graves病的母亲所生婴儿的NBSTT4水平高于一般以色列人群(p<0.001)。患有格雷夫斯病的母亲更经常使用辅助生殖技术(12.7%vs9.0%,分别,p=0.012;优势比[OR]1.46[95%置信区间[CI]1.03-2.07],p=0.031),并且有更多的妊娠期高血压(3.9%vs1.1%,p<0.001;OR3.53[95CI1.92-6.47],p<0.001),蛋白尿(2.5%对0.9%,p<0.001;OR3.03[95%CI1.43-6.45],p=0.004),剖宫产(26.4%vs19.7%,p=0.029;或1.46[95CI1.13-1.90],p=0.004),胎膜前破裂(15.4%vs4.1%,p<0.001;OR4.3[95CI3.13-5.91],p<0.001),和胎盘异常(5.1%vs2.0%,p<0.001;OR2.64[95CI1.57-4.44];p<0.001)。他们的婴儿的调整出生体重z评分较低(-0.18±0.94vs-0.03±0.90,p=0.007),并且更可能小于胎龄(12.0%vs8.1%,p=0.005;OR1.54[95CI1.08-2.19],p=0.018)。
    结论:新生儿甲状腺功能水平仅在妊娠期间疾病活跃时受到母体Graves病的影响。此外,孕产妇Graves病也与母婴二联的不良结局风险增加相关.
    Background: Graves\' disease has been associated with adverse pregnancy, labor and delivery, and neonatal outcomes. Thyroid function levels, assessed during newborn screening (NBS), can serve as indicators of the adaptation in the hypothalamic-pituitary-thyroid axis. We utilized data from the national thyroid NBS program to investigate the characteristics of the mother-infant dyad of term infants born to mothers with past or active Graves\' disease. Methods: The dataset of the Israeli NBS for thyroid function was linked with the electronic records of a tertiary medical center to generate a unified database of mothers and their term infants born between 2011 and 2021. The MDClone big data platform extracted maternal, pregnancy, disease course, labor and delivery, and neonatal characteristics of the mother-infant dyads. Results: Out of 103,899 registered mother-infant dyads, 292 (0.3%) mothers had past or active Graves\' disease. A forward multivariate linear regression demonstrated that Graves\' disease did not significantly affect NBS total thyroxine (tT4) levels (p = 0.252). NBS tT4 levels in infants born to mothers with active Graves\' disease were higher than those observed in the general Israeli population (p < 0.001). Mothers with Graves\' disease more frequently used assisted reproductive technology (12.7% vs. 9.0%, respectively, p = 0.012; odds ratio [OR] = 1.46 [CI 1.03-2.07], p = 0.031), and had more gestational hypertension (3.9% vs. 1.1%, p < 0.001; OR = 3.53 [CI 1.92-6.47], p < 0.001), proteinuria (2.5% vs. 0.9%, p < 0.001; OR = 3.03 [CI 1.43-6.45], p = 0.004), cesarean sections (26.4% vs. 19.7%, p = 0.029; OR = 1.46 [CI 1.13-1.90], p = 0.004), prelabor rupture of membranes (15.4% vs. 4.1%, p < 0.001; OR = 4.3 [CI 3.13-5.91], p < 0.001), and placental abnormalities (5.1% vs. 2.0%, p < 0.001; OR = 2.64 [CI 1.57-4.44]; p < 0.001). Their infants had lower adjusted birthweight z-scores (-0.18 ± 0.94 vs. -0.03 ± 0.90, p = 0.007) and were more likely to be small for gestational age (12.0% vs. 8.1%, p = 0.005; OR = 1.54 [CI 1.08-2.19], p = 0.018). Conclusions: Neonatal thyroid function levels were affected by maternal Graves\' disease only when the disease was active during gestation. Moreover, maternal Graves\' disease was also associated with an increased risk of adverse outcomes for the mother-infant dyad.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:葡萄牙新生儿筛查计划(PNSP)通过全国性筛查识别罕见疾病患者。目前,诊断出27种疾病,其中有24个先天代谢错误(IEM),覆盖约100%的新生儿(1)。2004年,国家实验室实施了新的筛选方法,串联质谱(MS/MS)测试氨基酸和酰基肉碱。这个新协议彻底改变了PNSP,并允许分析越来越多的IEM,治疗时机和临床结局明显改善(2)。
    方法:2004-2022年,采用MS/MS技术对1764830例新生儿进行筛查。那些显示表明IEM的生化特征的人通过基因组DNA提取进行分子表征,PCR扩增,和干血斑点样品的直接Sanger测序方法。
    结果:一组681名新生儿被诊断为IEM。MCAD缺陷是最常见的,233例确诊病例,主要显示c.985A>G(p。K329E)纯合性ACADM基因的突变。在33例确诊的I型戊二酸症病例中,约有1/3表现为c.120C>T纯合(p。GCDH中的Arg402Trp)突变。大约60%的MATII/III缺乏症病例显示MAT1A基因的显性突变,c.791G>A(p。Arg264His)。这些遗传图谱和其他被确定为24个IEM筛选的诊断确认。
    结论:该数据显示了通过新生儿筛查确定的IEM确诊患者的分子流行病学。在干血斑点样本中进行生化怀疑后,还检测到PNSP范围以外的一些疾病作为鉴别诊断。对PNSP的回顾性分析可以概述自实施MS/MS以来,国家IEM筛查所取得的18年成就。对于一些发病率低的病变,它很难找到一个明显的模式。然而,呈现这些疾病的从头突变可能为如何处理不同的表型提供见解。这项工作的目的是建立代谢疾病的分子流行病学筛查。
    BACKGROUND: The Portuguese Neonatal Screening Programme (PNSP) identifies patients with rare diseases through nationwide screening. Currently, 27 diseases are diagnosed, amongst which are 24 Inborn Errors of Metabolism (IEM), covering approximately 100% of neonates (1). In 2004, the national laboratory implemented a new screening method, tandem mass spectrometry (MS/MS) to test for amino acids and acylcarnitines. This new protocol revolutionized the PNSP and allowed for the analysis of an increased number of IEM, with clear improvements in treatment timings and clinical outcomes (2).
    METHODS: From 2004 to 2022, 1 764 830 neonates were screened with MS/MS technology. Those who displayed biochemical profiles indicating an IEM were subjected to molecular characterization via genomic DNA extraction, PCR amplification, and direct Sanger sequencing method of dried blood spot samples.
    RESULTS: A cohort of 681 newborns were diagnosed with an IEM. MCAD deficiency is the most frequent, with 233 confirmed diagnoses, showing predominantly c.985A>G (p.K329E) mutation of the ACADM gene in homozygosity. Approximately 1/3 of the 33 confirmed cases of Glutaric Aciduria type I present homozygous for the c.1204C>T (p.Arg402Trp) mutation in GCDH. Around 60% of cases of MAT II/III deficiency display the dominant mutation of the MAT1A gene, c.791G>A (p.Arg264His). These genetic profiles and others were determined as diagnostic confirmation for 24 of the IEM screened.
    CONCLUSIONS: This data shows the molecular epidemiology of patients with confirmed IEM diagnosis identified by neonatal screening. Some diseases out of the scope of the PNSP were also detected as a differential diagnosis after biochemical suspicion in the dried blood spot sample. The retrospective analysis of the PNSP allows for an overview of 18 years of achievements accomplished by the national screening for IEM since MS/MS was implemented. For some pathologies with low incidence, it\'s difficult to trace a discernible pattern. However, presenting de novo mutations for these diseases might provide insights on how to approach different phenotypes. The aim of this work is to establish the molecular epidemiology of metabolic diseases screened.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    评估新生儿代谢状态与随后呼吸道感染的严重程度之间的关系可能为感染发病机理提供重要见解。在这项多地点出生队列研究中,我们在发现队列中鉴定了出生后第一年与下呼吸道感染(LRTI)相关的新生儿代谢产物,并在两个独立队列中评估了复制情况.瓜氨酸浓度升高与LRTI几率降低相关(发现队列:aOR0.83[95%CI0.70-0.99],p=0.04;复制队列:aOR0.58[95%CI0.28-1.22],p=0.15)。虽然我们的发现需要进一步复制和研究作用机制,他们确定了LRTI预防和治疗的新目标。
    Assessing the association of the newborn metabolic state with severity of subsequent respiratory tract infection may provide important insights on infection pathogenesis. In this multi-site birth cohort study, we identified newborn metabolites associated with lower respiratory tract infection (LRTI) in the first year of life in a discovery cohort and assessed for replication in two independent cohorts. Increased citrulline concentration was associated with decreased odds of LRTI (discovery cohort: aOR 0.83 [95% CI 0.70-0.99], p = 0.04; replication cohorts: aOR 0.58 [95% CI 0.28-1.22], p = 0.15). While our findings require further replication and investigation of mechanisms of action, they identify a novel target for LRTI prevention and treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    简介:随着基因组测序的效用增加和成本降低,已经提出用新生儿基因组测序(nGS)来增强标准新生儿筛查(NBS)程序.在将nGS纳入新生儿筛查之前,必须更好地理解父母的观点。目标:使用对参加BabySeq项目的健康新生儿父母进行的调查数据,NGS与NBS的随机临床试验,本文报告了父母对结果披露后3个月评估的基于人群的NBS和NGS的态度。方法:父母对是否所有新生儿都应接受的态度,以及是否需要知情同意,NBS和NGS,以及是否应强制实施nGS使用5分量表进行评估,从强烈不同意(=1)到强烈同意(=5).父母对接收nGS结果类型的兴趣以5分制进行评估,从根本不感兴趣(=1)到非常感兴趣(=5)。使用Fisher精确检验分析了调查响应,配对t检验,和重复测量方差分析。结果:披露后3个月,174名健康新生儿的248名父母提交了一项调查。每个接受标准NBS的新生儿的支持(平均4.67)高于每个接受nGS的新生儿的支持(平均3.60;p<0.001)。NBS对所需知情同意的支持(平均3.44)低于nGS(平均4.27,p<0.001)。父母对NBS和NGS的态度与自我报告的政治倾向没有显着相关。如果假设在BabySeq项目之外接收nGS,大多数父母报告说,他们非常有兴趣接收关于他们的宝宝在儿童时期发展疾病的风险的信息,可以预防,治疗,或治愈(86.8%),以及他们在成年期患上可以预防的疾病的风险,治疗,或固化(84.6%)。讨论:父母的意见对于告知公共卫生计划的设计和交付至关重要,因为该计划的成功取决于父母的信任和参与。为了在不影响国家统计局当前高参与率的情况下适应父母的偏好,除NBS外,对NGS的可选附加同意可能是一种可行的方法。试验注册ClinicalTrials.gov标识符:NCT02422511。
    Introduction: With increasing utility and decreasing cost of genomic sequencing, augmentation of standard newborn screening (NBS) programs with newborn genomic sequencing (nGS) has been proposed. Before nGS can be integrated into newborn screening, parents\' perspectives must be better understood. Objective: Using data from surveys administered to parents of healthy newborns who were enrolled in the BabySeq Project, a randomized clinical trial of nGS alongside NBS, this paper reports parents\' attitudes regarding population-based NBS and nGS assessed 3 months after results disclosure. Methods: Parental attitudes regarding whether all newborns should receive, and whether informed consent should be required for, NBS and nGS, as well as whether nGS should be mandated were assessed using 5-point scales from strongly disagree (=1) to strongly agree (=5). Parents\' interest in receiving types of results from nGS was assessed on a 5-point scale from not at all interested (=1) to very interested (=5). Survey responses were analyzed using Fisher\'s exact tests, paired t-tests, and repeated measures ANOVA. Results: At 3 months post-disclosure, 248 parents of 174 healthy newborns submitted a survey. Support for every newborn receiving standard NBS (mean 4.67) was higher than that for every newborn receiving nGS (mean 3.60; p < 0.001). Support for required informed consent for NBS (mean 3.44) was lower than that for nGS (mean 4.27, p < 0.001). Parents\' attitudes toward NBS and nGS were not significantly associated with self-reported political orientation. If hypothetically receiving nGS outside of the BabySeq Project, most parents reported being very interested in receiving information on their baby\'s risk of developing a disease in childhood that can be prevented, treated, or cured (86.8%) and their risk of developing a disease during adulthood that can be prevented, treated, or cured (84.6%). Discussion: Parents\' opinions are crucial to inform design and delivery of public health programs, as the success of the program hinges on parents\' trust and participation. To accommodate parents\' preferences without affecting the current high participation rates in NBS, an optional add-on consent to nGS in addition to NBS may be a feasible approach. Trial Registration ClinicalTrials.gov Identifier: NCT02422511.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    BACKGROUND: Previous studies suggest that PAP-based CF protocols are suitable for newborn screening (NBS) for cystic fibrosis (CF) when newborns designated as CFSPID should not be detected. However, there are still discussions about the performance of IRT/PAP algorithms. We present the final results of a pilot study evaluating a IRT/PAP protocol with an IRT-dependent safety net (SN) conducted from 2008 to 2016 in southwestern Germany on nearly 500,000 newborns.
    METHODS: To achieve reliable data, all newborns were screened using both the PAP-based and a DNA-based CFNBS algorithm. PAP quantification and genetic analysis of the four most common CFTR mutations in Germany were performed in all newborns with IRT≥99.0 percentile. NBS was rated positive if either PAP was ≥1.6 µg/l and/or at least one CFTR mutation was detected. In addition, an IRT-dependent SN resulted in positive rating for both protocols if IRT was ≥99.9 percentile. To evaluate the IRT/PAP protocol, its performance was compared to that of the IRT/DNA protocol.
    RESULTS: The IRT/PAP protocol with IRT-based SN used in the study achieved a sensitivity of 94%, if false-negative detected neonates with meconium ileus and those designated as CFSPID were excluded from analysis. CF/CFSPID ratio was 92. However, PPV of the IRT/PAP+SN protocol was with 10.3% very low.
    CONCLUSIONS: PAP-based CFNBS protocols can be used, if less detection of CFSPID is desired. The IRT/PAP protocol with IRT-dependent SN evaluated here achieved adequate sensitivity but should probably be used in combination with a third-tier test to also achieve an acceptable PPV.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Knowledge about newborn screening (NBS) is an important factor for parents to make an informed decision about participation. In Europe, countries inform parents differently about their NBS program, potentially including different knowledge aspects in their information. The aim of this study was to assess twenty-six European parental information products and to analyze their knowledge aspects through a content analysis. The analyzed aspects were compared to a list of eight knowledge aspects from scientific literature. The list includes aspects important for parents\' decision-making, such as the purpose of screening. The study showed that most of the eight knowledge aspects are included in NBS information products of the majority of countries. However, there were differences between countries, for example in the amount of detail and phrasing of the information. Additional relevant knowledge aspects have also been identified and are recommended to optimize information products, such as the handling of residual bloodspot samples. This study only assessed knowledge aspects in information products meant for printing, but many countries also use other communication methods, and the impact on knowledge of the delivery of the information needs further study. Preferences of parents on alternative communication methods need to be considered and evaluated on their effectiveness.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号